ROLE OF FECAL MICROBIOTA TRANSPLANT IN SEVERE ULCERATIVE COLITIS
DOI:
https://doi.org/10.71000/d064k841Keywords:
Colitis, Ulcerative; , Enema, Fecal Microbiota Transplantation; , Intestinal Microbiota, Mayo Score, Remission Induction, Treatment OutcomeAbstract
Background: Ulcerative colitis is a chronic inflammatory bowel disease characterized by cycles of relapse and remission. Conventional therapies primarily target immune-mediated inflammation but often fall short in long-term disease control due to side effects, loss of response, and high costs. Fecal microbiota transplantation (FMT), a non-immunosuppressive approach aimed at restoring gut microbial balance, has shown promise in recurrent Clostridioides difficile infections. Its role in ulcerative colitis management, however, remains under investigation.
Objective: To compare the frequency of clinical remission with versus without fecal microbiota transplantation in the treatment of ulcerative colitis.
Methods: This randomized controlled trial was conducted at the Department of Gastroenterology, AIMC/Jinnah Hospital, Lahore, over six months from September 2021 to March 2022. A total of 180 patients diagnosed with active ulcerative colitis and meeting the inclusion criteria were enrolled and randomized into two groups. Group A received FMT via enema (50 g donor stool in 50 mL infusion) once weekly for six weeks. Group B received a placebo enema (50 mL sterile water) on the same schedule. Clinical remission was defined as a total Mayo score ≤2, assessed via endoscopy before and after the treatment period. Data were analyzed using SPSS v.25.
Results: The mean age was 38.81 ± 14.77 years in the FMT group and 37.74 ± 14.29 years in the control group. In the FMT group, 47 patients (52.2%) were male; in the control group, 68 (75.6%) were male. Baseline Mayo scores were similar (8.09 ± 1.50 vs. 7.94 ± 1.44; p = 0.510). After six weeks, the mean Mayo score was significantly lower in the FMT group (4.63 ± 2.40) than in controls (5.48 ± 2.18) (p = 0.015). Clinical remission was achieved in 32 (35.6%) patients in the FMT group and 17 (18.9%) in the control group (p = 0.012).
Conclusion: FMT was associated with a significantly higher clinical remission rate compared to standard treatment and may serve as a reliable adjunctive therapy for managing active ulcerative colitis.
References
Caruso R, Lo BC, Núñez G. Host–microbiota interactions in inflammatory bowel disease. Nature Reviews Immunology 2020:1-16.
Li Q, Ding X, Liu K, Marcella C, Liu X, Zhang T, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes. Clinical and Translational Gastroenterology 2020;11(8):e00224.
Haifer C, Leong RW, Paramsothy S. The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. Curr Opin Pharmacol 2020;55:8-16.
Sood A, Singh A, Mahajan R, Midha V, Mehta V, Gupta YK, et al. Acceptability, tolerability, and safety of fecal microbiota transplantation in patients with active ulcerative colitis (AT&S Study). J Gastroenterol Hepatol 2020;35(3):418-24.
Sood A, Singh A, Midha V, Mahajan R, Kao D, Rubin DT, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy. Crohn's & Colitis 360 2020;2(4).
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. Journal of gastroenterology 2021;56(6):489-526.
Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nature Reviews Gastroenterology & Hepatology 2021;18(1):67-80.
Biazzo M, Deidda G. Fecal microbiota transplantation as new therapeutic avenue for human diseases. Journal of clinical medicine 2022;11(14):4119.
Chen J, Li Y, Wang S, Zhang H, Du Y, Wu Q, et al. Targeting Clostridioides difficile: New uses for old drugs. Drug Discovery Today 2022;27(7):1862-73.
Tariq R, Pardi DS, Khanna S. Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. Therapeutic Advances in Gastroenterology 2023;16:17562848231174293.
Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal transduction and targeted therapy 2022;7(1):135.
Saleh A, Parsa S, Garza M, Quigley EMM, Abraham BP. The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis. Dig Dis. 2023;41(4):656-65.
Caenepeel C, Deleu S, Vazquez Castellanos JF, Arnauts K, Braekeleire S, Machiels K, et al. Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility. Clin Gastroenterol Hepatol. 2025;23(4):621-31.e7.
Wang Y, Cui B, Zhang F. Refractory ulcerative colitis stabilized by interval washed microbiota transplantation: less is more. Curr Med Res Opin. 2022;38(4):531-4.
Dang XF, Qing-Xi W, Yin Z, Sun L, Yang WH. Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series. BMC Gastroenterol. 2020;20(1):401.
Huang C, Huang Z, Ding L, Fu Y, Fan J, Mei Q, et al. Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis. J Transl Med. 2022;20(1):354.
Fehily SR, Basnayake C, Wright EK, Kamm MA. Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. J Gastroenterol Hepatol. 2021;36(10):2672-86.
Gefen R, Dourado J, Emile SH, Wignakumar A, Rogers P, Aeschbacher P, et al. Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials. Tech Coloproctol. 2025;29(1):103.
Malik S, Naqvi SAA, Shadali AH, Khan H, Christof M, Niu C, et al. Fecal Microbiota Transplantation (FMT) and Clinical Outcomes Among Inflammatory Bowel Disease (IBD) Patients: An Umbrella Review. Dig Dis Sci. 2025;70(5):1873-96.
Claytor JD, El-Nachef N. Fecal microbial transplant for inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2020;23(5):355-60.
Kedia S, Virmani S, S KV, Kumar P, Kante B, Sahu P, et al. Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. Gut. 2022;71(12):2401-13.
Zhao HL, Chen SZ, Xu HM, Zhou YL, He J, Huang HL, et al. Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta-analysis. J Dig Dis. 2020;21(10):534-48.
Green JE, Davis JA, Berk M, Hair C, Loughman A, Castle D, et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes. 2020;12(1):1-25.
Pinto S, Šajbenová D, Benincà E, Nooij S, Terveer EM, Keller JJ, et al. Dynamics of Gut Microbiota After Fecal Microbiota Transplantation in Ulcerative Colitis: Success Linked to Control of Prevotellaceae. J Crohns Colitis. 2025;19(2).
Chen Q, Fan Y, Zhang B, Yan C, Zhang Q, Ke Y, et al. Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation. Microbiol Spectr. 2023;11(3):e0415222.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Shehzad Aslam , Attique Abou Bakr, Muhammad Mobeen , Tayyab Shahzad , Arooj Haider (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
